insulin detemir · Levemir

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (2)
JP
  • Treatment of diabetes mellitus in cases where insulin therapy is indicated
Product first approved 2011PMDA
EU
  • Diabetes mellitus (Levemir, Novo Nordisk A/S); EMA page still lists it as authorised
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (37)
Type 1 Diabetes
NCT01831765 · Novo Nordisk A/S
2013-08-26 – 2015-06-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01513473 · Novo Nordisk A/S
2012-01-16 – 2013-07-30 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00474045 · Novo Nordisk A/S
2007-05 – 2010-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00623194 · Novo Nordisk A/S
2008-02 – 2009-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00435019 · Novo Nordisk A/S
2007-02 – 2008-09 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00447382 · Novo Nordisk A/S
2007-03 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00322257 · Novo Nordisk A/S
2006-05-01 – 2008-04-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00095082 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00184639 · Novo Nordisk A/S
2004-08-16 – 2005-11-22 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00605137 · Novo Nordisk A/S
2004-05-21 – 2005-04-23 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00595374 · Novo Nordisk A/S
2003-12-02 – 2004-10-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312156 · Novo Nordisk A/S
2002-08 – 2003-08 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00312104 · Novo Nordisk A/S
2002-04 – 2003-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01697657 · Novo Nordisk A/S
2001-09 – 2002-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01486940 · Novo Nordisk A/S
2002-03 – 2002-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT03220425 · Novo Nordisk A/S
2001-02-01 – 2001-11-12 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT00184600 · Novo Nordisk A/S
2004-11 – 2009-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00789191 · Novo Nordisk A/S
2008-11 – 2009-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00331604 · Novo Nordisk A/S
2006-08-31 – 2008-05-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00383877 · Novo Nordisk A/S
2006-09 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00504673 · Novo Nordisk A/S
2005-04 – 2006-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01709929 · Novo Nordisk A/S
2005-10 – 2006-04 · Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
What this study did
NCT00104182 · Novo Nordisk A/S
2005-02 – 2006-02 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00097084 · Novo Nordisk A/S
2004-09 – 2005-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00106366 · Novo Nordisk A/S
2005-03 – 2005-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00604253 · Novo Nordisk A/S
2003-12 – 2005-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00605020 · Novo Nordisk A/S
2003-12-02 – 2005-03-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00592527 · Novo Nordisk A/S
2004-04 – 2004-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01100892 · Sydney Children's Hospitals Network
2010-12 – 2023-02 · Cystic Fibrosis, Diabetes
What this study did
NCT04222348 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
2016-10-26 – 2020-07-01 · Diabetes, Gestational, Perinatal Disorder, Puerperal Disorder
What this study did
NCT01461616 · University of Aarhus
2012-02 – 2012-11 · Diabetes Mellitus, Type 1
What this study did
NCT00604344 · Novo Nordisk A/S
2003-04 – 2005-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00639626 · Nationwide Children's Hospital
2008-08 – 2010-05 · Cystic Fibrosis Related Diabetes
What this study did
Phase 2 (3)
Type 2 Diabetes
NCT05124457 · University of California, Los Angeles
2022-02-01 – 2025-06 · Gestational Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01595646 · Wake Forest University Health Sciences
2011-11 – 2015-03-12 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did
NCT01547169 · University of Washington
2011-03 – 2012-12 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did
Phase 1 (13)
Type 1 Diabetes
NCT01497574 · Novo Nordisk A/S
2005-05 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01542450 · Novo Nordisk A/S
2002-08 – 2003-02 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT00873223 · Novo Nordisk A/S
2009-03 – 2009-09 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01497600 · Novo Nordisk A/S
2004-02 – 2004-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01497561 · Novo Nordisk A/S
2003-03 – 2003-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00810589 · Medical University of Graz
2008-11 – 2008-12 · Diabetes, Type I
What this study did
NCT01498939 · Novo Nordisk A/S
2007-08 – 2007-09 · Diabetes, Healthy
What this study did
NCT01490099 · Novo Nordisk A/S
2006-08 – 2006-11 · Diabetes, Healthy
What this study did
NCT01498926 · Novo Nordisk A/S
2005-11 – 2006-02 · Diabetes, Healthy
What this study did
NCT01497587 · Novo Nordisk A/S
2005-08 – 2005-12 · Diabetes, Healthy
What this study did
NCT00760448 · Novo Nordisk A/S
2004-04 – 2005-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01497535 · Novo Nordisk A/S
2004-05-27 – 2004-10-31 · Diabetes, Healthy
What this study did
NCT02162407 · Novo Nordisk A/S
1999-10 – 1999-12 · Diabetes, Healthy
What this study did
Phase 4 (37)
Type 1 Diabetes
NCT00346996 · Lise Tarnow
2007-05 – 2012-08 · Type 1 Diabetes
What this study did
NCT01440439 · Buckinghamshire Healthcare NHS Trust
2011-11 – 2012-06 · Diabetes Mellitus, Type 1
What this study did
NCT00564395 · Montefiore Medical Center
2007-08 – 2010-05 · Type 1 Diabetes Mellitus
What this study did
NCT00542399 · Rabin Medical Center
2007-11 – 2010-03 · Type 1 Diabetes Mellitus
What this study did
NCT00509925 · Novo Nordisk A/S
2007-07 – 2008-07 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00313742 · Novo Nordisk A/S
2006-04 – 2006-11 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00117780 · Novo Nordisk A/S
2005-06 – 2006-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT02048189 · Centre Hospitalier Universitaire Dijon
2012-03-08 – 2015-02-26 · Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
What this study did
NCT00862875 · Institut de Recherches Cliniques de Montreal
2009-03 – 2014-04 · Type 2 Diabetes
What this study did
NCT01165684 · Novo Nordisk A/S
2010-10 – 2012-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01232491 · Novo Nordisk A/S
2010-10-29 – 2011-11-14 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01076842 · Novo Nordisk A/S
2008-04 – 2011-04 · Diabetes Type 2
What this study did
NCT00906529 · University of Texas Southwestern Medical Center
2009-05 – 2011-03 · Type 2 Diabetes
What this study did
NCT00795600 · Novo Nordisk A/S
2009-04 – 2010-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00909480 · Novo Nordisk A/S
2009-05 – 2010-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00699686 · University of Padova
2008-05 – 2010-03 · Type 2 Diabetes, Endothelial Dysfunction, Cardiovascular Disease
What this study did
NCT00998335 · University of Florida
2007-06 – 2010-02 · Type 2 Diabetes
What this study did
NCT00742976 · Copenhagen University Hospital, Rigshospitalet
2008-06 – 2009-12 · Diabetes Type 2, Weight Gain
What this study did
NCT00591227 · Rush University Medical Center
2008-05 – 2009-07 · Type 2 Diabetes Mellitus
What this study did
NCT00747409 · Munich Municipal Hospital
2004-07 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
NCT00537303 · Novo Nordisk A/S
2007-10 – 2009-03 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00506662 · Novo Nordisk A/S
2007-07 – 2008-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00634842 · Novo Nordisk A/S
2008-02 – 2008-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00455858 · Novo Nordisk A/S
2007-11 – 2008-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00590226 · Emory University
2006-12 – 2008-04 · Type 2 Diabetes
What this study did
NCT00467649 · AstraZeneca
2007-05 – 2008-04 · Type 2 Diabetes Mellitus
What this study did
NCT00521690 · Novo Nordisk A/S
2006-12 – 2007-08 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00274274 · Novo Nordisk A/S
2005-09 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00264901 · Novo Nordisk A/S
2005-10 – 2006-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT00607737 · Lise Tarnow
2008-01 – 2010-07 · Diabetes Mellitus
What this study did
NCT00941148 · ikfe-CRO GmbH
2008-04 – 2009-03 · Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment
What this study did
NCT00542620 · Novo Nordisk A/S
2007-09 – 2009-03 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00490893 · University Hospital Tuebingen
2006-03 – 2006-12 · Diabetes Mellitus, Hypoglycemia
What this study did
NCT00566124 · University of Aarhus
2005-01 – 2005-05 · Diabetes
What this study did
Early phase / not applicable (9)
Type 1 Diabetes
NCT00626080 · Amsterdam UMC, location VUmc
2009-01 – 2011-12 · Type 1 Diabetes
What this study did
NCT00564018 · University of Texas Southwestern Medical Center
2006-09 – 2011-04 · Type 1 Diabetes
What this study did
NCT00659165 · University of New Mexico
2008-04 – 2011-01 · Diabetes Mellitus
What this study did
Type 2 Diabetes
NCT01232946 · Indiana University
2012-01 – 2017-09-08 · Type 2 Diabetes
What this study did
NCT01281605 · Mackay Memorial Hospital
2011-01 – 2016-05 · Type 2 Diabetes
What this study did
NCT01837680 · St. Luke's-Roosevelt Hospital Center
2013-03 – 2015-03 · Diabetes, Gestational, Diabetes, Type 2
What this study did
NCT01420692 · Ankara University
2010-06 – 2012-06 · Type 2 Diabetes Mellitus
What this study did
NCT01377155 · Diabetes Care Center
2011-06 – 2011-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT01239550 · Vanderbilt University
2011-04 – 2028-12 · Diabetes, Obesity
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Type 1 Diabetes
NCT03377699 · Novo Nordisk A/S
2017-11-22 – 2020-12-17 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT01616784 · Sheffield Teaching Hospitals NHS Foundation Trust
2011-11 – 2015-11 · Type 1 Diabetes
What this study did
NCT01074268 · Novo Nordisk A/S
2010-02 – 2010-12 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00978627 · Novo Nordisk A/S
2009-08 – 2010-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
NCT00487240 · Eli Lilly and Company
2007-06 – 2008-08 · Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01003184 · AstraZeneca
2009-10 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT00271284 · Sanofi
2005-10 – 2008-09 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (1)
Type 1 Diabetes
NCT00841087 · Novo Nordisk A/S
2009-01 – 2009-05 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Phase 1 (4)
Type 1 Diabetes
NCT06685185 · Novo Nordisk A/S
2024-11-12 – 2026-03-18 · Diabetes Mellitus, Type 1
What this study did
NCT01135927 · Novo Nordisk A/S
2010-06 – 2010-10 · Diabetes, Diabetes Mellitus, Type 1
What this study did
Type 2 Diabetes
NCT01043510 · Novo Nordisk A/S
2010-01 – 2010-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 4 (5)
Type 2 Diabetes
NCT02451137 · Sanofi
2015-06-16 – 2018-08-09 · Diabetes Mellitus, Type 2
What this study did
NCT00657943 · Steno Diabetes Center Copenhagen
2008-04 – 2012-12 · Type 2 Diabetes, Atherosclerosis, Arteriosclerosis
What this study did
NCT00405418 · Sanofi
2006-11 – 2008-06 · Diabetes Mellitus, Type 2
What this study did
Early phase / not applicable (1)
Type 2 Diabetes
NCT01310452 · Fudan University
started 2011-01 · Type 2 Diabetes Mellitus
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Other / comorbidity
NCT02741687 · Emory University
2016-06 – 2017-04 · Hyperglycemia
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Detemir (Levemir): this drugApprovedPeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
IcoSema (Kyinsu)Phase 3PeptideInsulin receptor (basal), GLP-1 receptorPartial signal
NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001)
NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01)
Insulin Sudelidec (INS068)Phase 3PeptideInsulin receptor (basal)Partial signal
NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%)
NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%)
SHR-3167Phase 3PeptideInsulin receptor (basal)Partial signal
NCT06688123: Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.
GZR101Phase 2PeptideInsulin receptor (basal)Partial signal
NCT06199505: Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%).
IcovamenibPhase 2Small moleculeMeninPartial signal
NCT05731544: icovamenib showed a mean reduction in HbA1c of 0.36% (p=0.022). The strongest performing arm was Arm B (icovamenib dosed at 100mg QD for 12 weeks) with a mean HbA1c reduction of 0.5% (p=0.012).
UBT38006Phase 1PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 73 furthest-along competitors are listed; 77 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Levemir (insulin detemir) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Early phase / not applicableDiabetes, ObesityActive not recruiting
Est. primary completion 2028-12 · NCT01239550 · CT.gov ↗
What to watch

See the full readout calendar ↗